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Abstract
Studies of the human immunodeficiency virus type 1 (HIV-1) continue to enrich eukaryotic biology
and immunology. Recent advances have defined factors that function after viral entry and prevent
the replication of proviruses in the infected cell. Some of these attack directly viral structures
whereas others edit viral genetic material during reverse transcription. Together, they provide
strong and immediate intracellular immunity against incoming pathogens. These processes also
offer a tantalizing glimpse at basic cellular mechanisms that might restrict the movement of mobile
genetic elements and protect the genome.
Background
Although it is highly pathogenic in humans, HIV-1 cannot
replicate in most other species [1]. This tropism is deter-
mined primarily by whether host cells express the
required cofactors. For example, by lacking a functional
receptor and appropriate transcriptional machinery,
mouse cells do not support infection by HIV-1. Thus, the
organism resists the pathogen via a cell-based incompati-
bility. However, a pathogen can also be restricted by the
presence of dominant inhibitory factors. They attack the
incoming virus directly and block its integration into the
host genome. This situation also pertains to HIV-1 in
mouse cells and represents true "intracellular immunity."
Importantly, this host response is more rapid than either
traditional innate or adaptive immunity and can prevent
the establishment of the infection.
Recent advances in our understanding of intracellular
immunity have identified two different proteins, the tri-
partite motif protein 5α  (TRIM5α ) [2] and the apolipo-
protein B mRNA-editing enzyme catalytic-polypeptides
3B, 3F and 3G (APOBEC3B, APOBEC3F and APOBEC3G
or A3B, A3F and A3G), which collectively inactivate sev-
eral retroviruses including HIV-1, simian immunodefi-
ciency virus (SIV), hepatitis B virus and some mouse
mobile genetic elements [3-7]. This review highlights
these recent developments and mentions briefly addi-
tional potential blocks to retroviral replication.
Interference and Restriction
Let us begin with some definitions and historical perspec-
tives. Viral "interference" refers to the situation when cells,
which are chronically infected with one virus or contain
endogenous retroviruses, resist superinfection by other
viruses bearing envelopes with a similar target specificity.
This block usually results from the loss of the appropriate
receptor on the cell surface. A good example of this inter-
ference is the Friend virus susceptibility factor 4 (Fv4),
also known as Akvr-1, which controls the susceptibility of
mice to infection by ecotropic but not other murine leuke-
mia viruses (MLVs) [8]. This gene is located on mouse
chromosome 12 [9] within an endogenous defective
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provirus and encodes a complete envelope [10] that
shares very high sequence similarity with those from eco-
tropic Cas-Br-E virus and Moloney MLV [11]. This enve-
lope then blocks the expression of the cationic amino acid
transporter, which is the receptor for these MLVs, on the
cell surface (Fig. 1) [12]. Of interest, MLV can only use the
murine but not the human form of this receptor for entry.
The term "restriction" refers to intracellular blocks to viral
replication. Until now, the best example has been Fv1
[13]. Like Fv4 and the less well-characterized Fv3 and Fv2,
Fv1 also confers resistance of mice to the infection by MLV
(Figs. 1 and 2). The Fv1 gene is located on mouse chromo-
some 4 [14] and encodes a protein that resembles other
endogenous retroviral structural group specific antigens
(Gag) (Fig. 2) [15]. Of note, during the morphogenesis
and release of progeny virions, retroviral Gag polyproteins
are processed by the viral protease into distinct subunits,
namely matrix (MA), capsid (CA) and nucleocapsid (NC).
Whereas MA and CA form the outer shell and inner core
of mature viral particles, NC packages viral genomic RNA
into the core [16]. After entry and uncoating in newly
Effective intracellular immunity targets incoming viruses Figure 1
Effective intracellular immunity targets incoming viruses. Whereas the ecotropic murine leukemia virus (MLV) (represented as 
a viral particle in blue) encounters Fv4 and Fv1 blocks, other retroviruses such as HIV-1, SIV and EIAV (represented as a viral 
particle in brown) encounter TRIM5α  and cytidine deaminase blocks. Fv4 prevents the entry by ecotropic MLV by sequestering 
the viral receptor from the cell surface. Fv1 targets MLV CA and stops the nuclear import of the viral preintegration complex 
(PIC). TRIM5α  also targets retroviral CA and blocks uncoating. hA3B, hA3F and hA3G deaminate cytidines on newly synthe-
sized retroviral cDNA and disrupt viral replication. Capital red letters highlight the points of inhibition. Viral structural compo-
nents, nucleic acids, RNA and DNA, and intracellular events are represented in different colors.Retrovirology 2005, 2:25 http://www.retrovirology.com/content/2/1/25
Page 3 of 13
(page number not for citation purposes)
infected cells, many structural proteins remain associated
with viral enzymes (reverse transcriptase, RT and
integrase, IN) and RNA in a large (2 mDa) preintegration
complex (PIC).
Alleles of Fv1 in Balb/c (Fv1b/b) and NIH/Swiss (Fv1n/n)
mice result in resistance to N- and B-tropic strains of MLV,
respectively, which maps to position 110 in CA (Fig. 2)
[17]. A recent structural analysis revealed that this residue
is located at the outer face of the core structure of CA with
easy access to cellular proteins [18]. On Fv1, the key resi-
due for this restriction was mapped to position 358 (Fig.
2) [19]. Although binding between CA and Fv1 has not
been demonstrated, they could interact as higher order
structures, especially since CA and Gag form oligomers, in
the case of CA, hexagonal lattices of the viral core. As het-
erozygous Fv1n/b mice block infection by both viruses,
resistance is dominant [20]. Conversely, NB-tropic MLV
can infect all these mice. Of interest, this restriction is sat-
urable with high levels of CA from either virus [21],
implying that amounts of Fv1 or its cofactor/s are limit-
ing. As described below, one of these cofactors could be
TRIM5α  [22]. As a result of these interactions, Fv1 is
thought to block the disassembly of CA and the normal
movement of the PIC into the nucleus (Fig. 1) [23,24].
TRIM5α
Fv1 is not the only genetic system conferring intracellular
immunity against a retroviral infection. For example, the
replication of N-tropic MLV and the equine infectious
anemia virus (EIAV, a lentivirus) is also inhibited in
human cells [25], as is that of the primate lentiviruses
HIV-1 and SIV from rhesus macaques (SIVmac) in cells
from different monkeys (Fig. 3) [26-29]. For example,
HIV-1 does not grow in old world monkeys, which
include African green monkeys and rhesus macaques, and
Fv1 block in MLV infection Figure 2
Fv1 block in MLV infection. Ecotropic MLVs (e.g. Friend MLV) fall into two categories with respect to their host range: N-
tropic strains infect NIH/Swiss mice (brown) much more efficiently than BALB/c mice (black), whereas B-tropic strains display 
the opposite preference. Based on their susceptibility to N- or B-tropic virus, mice were classified into Fv1n/n (NIH/Swiss) and 
Fv1b/b (Balb/c) strains. These viruses differ at a single residue at position 110 in CA (presented below the NIH/Swiss mouse). 
These changes are matched by residues at position 358 in Fv1n and Fv1b proteins (presented below the Balb/c mouse).Retrovirology 2005, 2:25 http://www.retrovirology.com/content/2/1/25
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SIVmac does not infect new world monkeys, which include
squirrel monkeys and common marmosets (Fig. 3) [26-
29].
Interestingly, these blocks resemble Fv1 restriction in sev-
eral ways. First, viral replication is impaired at the step of
reverse transcription [25-28]. Second, CA is also targeted.
The residue at position 110 in CA also determines the
restriction of N-tropic MLV in human cells [25] and that
of HIV-1 in rhesus macaque cells is abrogated when its CA
is replaced by that from SIVmac [29]. Third, because het-
erokaryons between non-restrictive and restrictive cells
maintain the inhibition, this restriction is dominant
[27,28]. Finally, these blocks are saturable. However,
since no Fv1-related gene could be found in primate cells,
blocks to N-tropic MLV and EIAV in human cells were
thought to be due to the restriction factor 1 (Ref1) [25],
and those to HIV-1 and SIV in monkey cells to the lentivi-
rus susceptibility factor 1 (Lv1) (Fig. 3) [27].
Indeed, Ref1 and Lv1 share additional similarities in
blocking retroviral replication. For examples, both restric-
tions can be attenuated by chemicals that disrupt the
integrity of mitochondrial membranes [30,31], and they
Blocks to retroviral replication by different TRIM5α  proteins from several species Figure 3
Blocks to retroviral replication by different TRIM5α  proteins from several species. The replication of HIV-1 is blocked by 
TRIM5α  from old world monkeys and owl monkeys, but not human and new world monkeys (left top panel). The replication 
of SIV is blocked by TRIM5α  proteins from new world monkeys, but not from humans, old world monkeys, and owl monkeys 
(right top panel). The replication of N-MLV is prevented by TRIM5α  proteins from dogs, pigs, cows, old world monkeys, and 
humans, but not mice (left bottom panel). The replication of EIAV is blocked by TRIM5α  from human and old world monkeys, 
but not horses (right bottom panel). In all cases, arrows indicate no inhibition.Retrovirology 2005, 2:25 http://www.retrovirology.com/content/2/1/25
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can be saturated by the same virus like particles (VLPs)
[32]. Using a functional complementation assay, Lv1 was
first identified as the rhesus macaque TRIM5α
(macTRIM5α ) gene [2]. Later, by eliminating TRIM5α
transcripts from old world monkey and human cells with
small interfering RNA (siRNA), the Lv1 and Ref1 blocks
were also abrogated [33]. Further studies revealed that
hTRIM5α  (from humans), macTRIM5α  and agmTRIM5α
(from African green monkeys) restrict the replication of
different viruses, which were assigned previously to Lv1
and Ref1 (Fig. 3) [22,33-35]. Thus, Ref1 and Lv1 are spe-
cies-specific variants of TRIM5α .
The hTRIM5α  protein contains 493 residues (Fig. 4) and
belongs to the large tripartite motif (TRIM) family that
consists of 37 genes, which include the promyelocytic
leukemia (PML or TRIM19) protein [36]. By alternative
RNA splicing, they produce 71 different transcripts. For
example, the human TRIM5 gene is expressed as
hTRIM5α , β , γ , σ , ε , and ζ . Although little is known of
their function, they contain three distinctive structural
motifs, a RING Zn++ finger, one or two B-box Zn++ finger,
and an α -helical coiled-coil (CC) region (Fig. 4). For this
reason, they are also called the RING finger:B box:Coiled-
coil (RBCC) family proteins. The RING finger motif fea-
tures a cysteine-rich consensus, which contains two inter-
leaved Zn++-binding sites [37]. Many RING finger proteins
act as E3 ubiquitin ligases and play key roles in protein
degradation. For example, Ring-box-1 (Rbx1) is an essen-
tial component of the Skp1:cullin-1:F-box (SCF) complex.
Additionally, TRIM5σ  displays E3 ligase activity in vitro
[38]. B-boxes, which consist of one Zn++-binding site and
a B1 or B2 motif [39], orient the CC motif that mediates
protein-protein interactions. Indeed, TRIM proteins form
oligomers [36]. In addition, TRIM5α  contains a SPRY
domain at its C-terminus (Fig. 4). The SPRY domain was
originally identified in the splA kinase of Dictyostelium
and the rabbit ryanodine receptor [40], and belongs to the
subclass of the B30.2 or RFP-like domains. In butyrophi-
lin, the B30.2 domain, which contains 170 residues, is
involved in ligand binding [41]. Of interest, TRIM pro-
teins localize to particular cellular compartments where
they form discrete structures. Whereas TRIM19 assembles
discrete PML oncogenic domains (PODs) in the nucleus,
TRIM5α  can form cytoplasmic bodies [36].
Although they share 87% sequence similarity, only
macTRIM5α  but not hTRIM5α  blocks HIV-1 replication
[2]. This species-specific restriction was mapped to the
SPRY domain [42-44]. Through genetic analysis, it was
revealed that this SPRY domain has experienced dramatic
mutations during primate evolution [45] and contains
four variable regions V1, V2, V3, and V4 [46]. The change
of a single residue (R332P) in V1 abolished the inhibition
of HIV-1 replication by hTRIM5α  [43,44], which suggests
that the SPRY domain is responsible for its targeting of
CA. Although no binding between the SPRY of rhTRIM5α
and HIV-1 CA has been demonstrated, the findings with
TRIM5α  from owl monkeys (omTRIM5α ) support such
direct interactions [47,48]. A rather complicated story fol-
lows. Cyclophilin A (CypA) is an eukaryotic peptidyl-pro-
lyl cis-trans-isomerase. It binds an exposed proline-rich
loop in CA of HIV-1 and is critical for its replication in
human cells [49,50]. In contrast, the ability to bind CypA
restricts HIV-1 replication in owl monkey cells. Owl mon-
keys are atypical new world monkeys because their Lv1
inhibits HIV-1 but not SIVmac. Although this block to HIV-
1 replication is abrogated when the interaction between
CA and CypA is prevented by mutations in CA or by
cyclosporin A treatment in owl monkey cells, the same
manipulations increase effects of Ref1 on HIV-1 in human
cells [51]. The explanation for these differences came with
the cloning of the omTRIM5α  gene. Instead of the SPRY
domain, it contains the complete CypA gene [47,48] (Fig.
4). Thus, owl monkey cells express a fusion protein
between omTRIM5α  and CypA (omTRIM5α .Cyp), which
most likely arose from a retrotransposition of the CypA
gene into the omTRIM5α  locus by the long interspersed
nuclear elements-1 (LINE-1 or L1). In conclusion, CA and
omTRIM5α  interact via this CypA domain and restrict
HIV-1 replication in owl monkeys.
These studies suggest that Fv1 and TRIM5α  might interact
directly with CA to block incoming viruses. However, in
contrast to Fv1, which blocks nuclear entry and integra-
tion of the provirus [23,24], TRIM5α  inhibits viral
replication at a step before reverse transcription (Fig. 1). It
is puzzling why such differences exist. An answer might lie
in the observation that MLV, but not HIV-1, retains its CA
in the reverse transcription complex [52,53]. Thus, the
uncoating of HIV-1 could proceed much faster than that
of MLV. Once the core structure is destroyed, the reverse
transcription complex could become more susceptible to
TRIM5α . TRIM5α  could then trigger the proteasomal
degradation of PIC. This model also offers an explanation
of the enhancement of viral replication when target cells
are treated with proteasomal inhibitors [54]. Further
details await studies of other proteins that interact with
Fv1 and TRIM5α , their enzymatic properties and traffick-
ing in cells.
Cytidine deaminases
In addition to Fv1 and TRIM5α , host cells have developed
additional mechanisms to protect themselves from viral
invasion. The next important block involves nucleic acid
editing of viral reverse transcripts. For a long time, it had
been noted that retroviruses contain a high frequency of G
to A transitions [55,56]. In certain strains of HIV-1, up to
60% of all guanidines are replaced by adenines [57]. Pre-
viously, this G to A hypermutation was attributed to theRetrovirology 2005, 2:25 http://www.retrovirology.com/content/2/1/25
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high error rate of reverse transcriptase and the imbalance
in dCTP pools in cells [58]. However, we now know that
host cellular cytidine deaminases are responsible.
In parallel, mutant HIV-1 lacking the viral infectivity fac-
tor (Vif) (HIV-1∆ Vif) can only replicate in certain T cell
lines, which are called "permissive" cells. In other "non-
permissive" cells, only wild type HIV-1 but not HIV-1∆ Vif
can replicate [59,60]. Because heterokaryons between per-
missive and non-permissive cells do not support the rep-
lication of HIV-1∆ Vif, there exists a dominant inhibitor in
these non-permissive cells [61,62]. By subtractive cloning
between non-permissive CEM and permissive CEM-SS T
cells, the inhibitory factor was identified as the human
A3G (hA3G) protein [3]. Later, its close relatives hA3F,
and to a lesser degree, hA3B, were found to possess similar
anti-viral activities [4-7].
The human APOBEC family comprises 10 proteins,
among which are the founding member APOBEC1 (A1)
and the activation induced deaminase (AID) [63]. They
contain one (e.g. APOBEC1 and AID) or two (e.g. hA3F
and hA3G) Zn++-binding deaminase motifs with the con-
sensus sequence His-X-Glu-X23–28-Pro-Cys-X2–4-Cys
(where X denotes any amino acid) [63]. They can target
cytosines and convert them to uracils (C to U transitions)
on DNA or RNA (e.g. A1) templates. During the second-
strand DNA synthesis, these C to U transitions are then
converted to those of G to A. For example, by changing
C6666 to U6666, A1 introduces a stop codon at position
Schematic representations of hTRIM5α , macTRIM5α , and omTRIM5a Figure 4
Schematic representations of hTRIM5α , macTRIM5α , and omTRIM5a. CypA proteins. hTRIM5α  contains 493 residues and 
four conserved motifs, whose positions are given. They are the RING domain, B box, coiled-coil and SPRY domains. The latter 
domain is required for species-specific restriction of primate lentiviruses and is diagrammed in red. A key residue in this 
domain, which is the arginine at position 332 in hTRIM5α , or the proline at position 334 in macTRIM5α , is responsible for its 
species-specific inhibition of lentiviral replication. omTRIM5α  from owl monkeys contains an N-terminal omTRIM5α  sequence 
to position 299, linked in-frame to the entire CypA gene (147 residues)(omTRIM5α .CypA).Retrovirology 2005, 2:25 http://www.retrovirology.com/content/2/1/25
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6666 into the apolipoprotein B100 mRNA, which is trans-
lated into the truncated apolipoprotein B48 (48 kDa) pro-
tein [64]. AID also directs the cytidine deamination at
specific "hot spots" to direct somatic hypermutation and
isotype class switching in B cells [65]. hA3F and hA3G
block retroviral infection in hematopoietic cells. They
share overall 70% sequence similarity and form
homodimers as well as mixed oligomers [5]. Physiologi-
cal functions of these proteins are not yet defined, except
that hA3G also inhibits the movement of some mouse
mobile genetic elements in cells [66]. Thus, they could
contribute to the stability of the genome.
APOBEC proteins and viral replication
The mechanisms for antiviral activities of APOBEC pro-
teins have been characterized extensively. In the absence
of Vif, hA3F and hA3G are incorporated into virions. They
are then transferred from producer to target cells by the
virus. Following viral entry and uncoating, reverse tran-
scription is initiated and viral minus-strand cDNA is syn-
thesized. During this process, these APOBEC proteins
attack newly synthesized minus-strand cDNAs and intro-
duce C to U transitions [67-70], which block viral replica-
tion by several mechanisms [71]. First, since uracils are
not tolerated in DNA, they are removed by uracil N-gly-
cosidases (UNG) from DNA and these nicked DNA are
further cleaved by the host DNA-repair enzymes like apu-
rinic/apyrimidinic endonuclease-1 (APE1). Fragmented
DNA neither integrates nor replicates. Second, should
edited proviruses survive and integrate, the new G to A
changes on the plus strand DNA also create havoc on viral
transcripts. These changes could lead to alternate splicing
and the production of nonfunctional proteins. To these
ends, hA3G and hA3F have different sequence prefer-
ences. Whereas hA3G favors repeated deoxycytidines (GG
on the opposite strand) [72], hA3F prefers deoxycytidines
followed by deoxythymidines (GA on the opposite
strand) [4,7].
The key step for the anti-viral activity of hA3G is its incor-
poration into virions. Although the encapsidation of
hA3G requires NC of HIV-1 Gag, it is still controversial
whether this interaction is mediated by RNA [73-76].
Since both NC and hA3G can bind RNA, this recruitment
most likely reflects RNA-protein, as well as protein-pro-
tein, interactions [77,78]. Nevertheless, since hA3G
blocks the replication of all primate lentiviruses in the
absence of Vif (HIV-1, HIV-2, and SIV) [3,79,80], EIAV
[69], HBV [81,82], and some mouse mobile genetic
elements [66], these interactions must have broad specifi-
cities. For example, hA3F has the same effect against HIV-
1, SIV and HBV and hA3B and hA3C block SIV (Table 1)
[4-7,83,84]. Of interest, the rat but not human A1 pro-
teins block HIV-1 by directly deaminating viral RNA [85].
Vif and APOBEC proteins
In contrast to HIV-1∆ Vif, wild-type HIV-1 is not restricted
in non-permissive cells. Thus, Vif counteracts the effects of
hA3F and hA3G. Indeed, Vif binds and triggers the
degradation of these APOBEC proteins in producer cells,
thus blocking their incorporation into virions [86-88].
Initially, Vif was demonstrated to interact with cellular
proteins Cul5, elonginB, elonginC, and Rbx1 to form a
cullin-based E3 ubiquitin ligase complex [89], which dis-
plays striking similarities to SCF complex. Later, Vif was
found to contain a conserved suppressor of cytokine sign-
aling (SOCS) box-like motif (SLQ(Y/F)LA) that binds
elongin C, which in turn recruits elongin B, cullin 5 and
Rbx1, thus forming the ElonginB/C-Cul5-SOCS-box
(ECS) E3 ubiquitin ligase complex [90,91]. As a conse-
quence of these interactions, APOBEC proteins are
polyubiquitylated and degraded [86-88]. In parallel,
some groups observed that Vif triggers only a marginal
degradation of hA3G, which suggested that Vif could
sequester hA3G from encapsidation through a degrada-
tion-independent mechanism [79,92].
Although Vif blocks the antiviral activity of hA3G, its
activity is highly species-specific (fig. 5). Additionally as
presented in Table 2, Vif from HIV-1 blocks A3G proteins
from humans and chimpanzees (hA3G and chA3G), but
not from old world monkeys, Vif from SIVmac blocks all
Table 1: Abilities of APOBEC proteins to inhibit viruses and retrotransposons
Species APOBEC proteins HIV-1∆ Vif HIV-2∆ Vif SIV∆ Vif MLV EIAV HBV L1 IAP MusD
humans A3B + + -
A3C - + -
A3F + + +
A 3 G + + + +++ - +
old world monkeys A3G + + -
rats A1 + -
mice A3 + + - - +
(+) block, (-) do not blockRetrovirology 2005, 2:25 http://www.retrovirology.com/content/2/1/25
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A3G isoforms from human and non-human primates,
and Vif from SIVagm only blocks A3G proteins from mon-
keys [79]. In addition, hA3F can be inactivated by Vif pro-
teins from HIV-1, HIV-2, and SIVmac, but not from SIVagm
[4,5,84]. Moreover, the hA3C can be inactivated by Vif
from SIVmac [84] and no Vif protein can inactivate the
hA3B, rat A1, or mouse APOBEC3 (mA3) proteins [6].
Efforts have been made to uncover the molecular mecha-
nisms of these species-specific differences, and agmA3G
was chosen because it is most similar to hA3G. It was
found that Vif from HIV-1 fails to inactivate agmA3G
because it contains a lysine rather than aspartate at posi-
tion 128 (K128D), which is found in hA3G. Although
agmA3G neither binds Vif nor is excluded from virions,
the mutant agmA3G protein bearing D128 becomes fully
sensitive to Vif from HIV-1 [93-96]. In addition, the recip-
rocal exchange of D for K at position 128 in hA3G renders
it resistant to Vif. Structural comparisons with the related
cytidine deaminases from E.coli reveal that D128 maps to
an α -helical turn on an exposed loop [96]. Since the same
K128 residue also exists in A3G from rhesus macaque
(macA3G), its sensitivity might also be altered with a sim-
ilar K128D substitution. Although these studies estab-
lished the correlation between the ability of Vif to
neutralize APOBEC proteins and viral replication, it is
unlikely that these species-specific susceptibilities of
Species-specific inhibition of APOBEC3 (A3) proteins by Vif Figure 5
Species-specific inhibition of APOBEC3 (A3) proteins by Vif. HIV-1 and SIV can incorporate A3 proteins from all these species 
into virions. However, Vif from HIV-1 (VifHIV, brown), can only inhibit A3 proteins from humans and new world monkeys) but 
not those from old world monkeys and mice. In contrast, Vif from SIVmac (VifSIV, green) can inactivate A3 proteins from old and 
possibly new world monkeys, but not from humans and mice). In this drawing, stick figures represent sources of A3 proteins 
and not targets of infection.Retrovirology 2005, 2:25 http://www.retrovirology.com/content/2/1/25
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APOBEC proteins to Vif are responsible for the transmis-
sion of primate lentiviruses to new host species [97].
Viruses that lack Vif and mobile genetic 
elements
How can viruses that do not encode Vif escape from this
intracellular immunity?
As some APOBEC proteins also inhibit the replication of
EIAV, HBV, and MLV, there must be additional mecha-
nisms of escape. In the case of EIAV, it encodes an addi-
tional enzyme, which is named dUTPase [98]. This
enzyme is also produced by herpesviruses, poxviruses,
and some other retroviruses. Recently, it was demon-
strated that dUTPase from caprine arthritis encephalitis
virus (CAEV) could block the misincorporation of dUTP
during HIV-1 reverse transcription [99]. Thus, its dUTPase
could also protect EIAV from attack by APOBEC proteins.
In the case of HBV, it replicates in tissues that do not
express hA3G [63]. The situation for MLV is more compli-
cated. Unlike human cells that express seven A3 proteins,
the mouse genome contains only one A3 gene. Although
mA3 blocks the replication of HIV-1 and SIV, it is less effi-
ciently packaged into and does not inhibit MLV [100]. In
contrast, hA3G blocks the replication of MLV. Thus, MLV
has adapted to its natural host by a mechanism that
remains poorly understood.
What is the situation with mobile genetic elements that
resemble retroviruses? In humans and mice, there are sev-
eral types of retrotransposons [101]. The most abundant
are LINE-1 or L1 elements that do not contain long termi-
nal repeats (LTRs). Up to one hundred human and several
thousand mouse L1 elements are functional [101].
Although they require reverse transcription, they do not
form VLPs and APOBEC proteins do not block their
replication [66,102]. In contrast, LTR-containing retro-
transposons, which represent up to 10% of the human
genome, form VLPs, bud from intracellular organelles and
behave similarly to incoming exogenous retroviruses.
Although no active human endogenous retroviruses
(HERVs) have been found, in the mouse, there are several
hundred active intracisternal A-particles (IAPs) [103] and
at least ten copies of MusD [104]. Indeed, sequences of
IAPs and MusDs contain frequent G to A transversions in
their genomes [66]. In addition, using transient expres-
sion assays in cells, hA3G and mA3 inhibit the retrotrans-
position of IAP and MusD (Table 1) [66]. Thus, APOBEC
proteins also block the movement of some mobile genetic
elements, most likely in germ cells and during embryo-
genesis, in mammals.
Other antiviral genes that contribute to 
intracellular immunity
Besides these predominant blocks to viral replication in
cells, additional barriers have been described at levels of
transcription and RNA stability, as well as assembly of
progeny virions. However, since they do not block the
integration of proviruses into the host genome, they play
lesser roles in intracellular immunity. First, Murr1 blocks
the activation of NF-κ B in resting cells and thus the induc-
tion of HIV-1 replication [105]. Second, a sophisticated
genetic screen looking for cells that survive attack by
MuLV bearing the thymidine kinase (tk) gene (which
would otherwise succumb to trifluorothymidine that is
phosphorylated by tk) revealed the Zn++-finger antiviral
protein ZAP that degrades rapidly MLV transcripts [106].
ZAP binds a specific sequence at the 3' end of viral, but not
cellular, transcripts and leads to their rapid degradation in
the exosome. This mechanism appears analogous to tris-
tetraprolin, which binds AU-rich RNA species (e.g. those
coding for cytokine genes) and targets them for rapid deg-
radation in the cytoplasm. Apparently, not only are retro-
viral transcripts targeted by ZAP, but it destroys Ross River,
Semliki, Sindbis and Venezualan equine encephalitis
viruses, all of which belong to the alphavirus family [107].
Table 2: Species-specific susceptibility of APOBEC proteins to Vif
APOBEC proteins Species HIV-1 Vif HIV-2 Vif SIVagm Vif SIVmac Vif
A3G humans + + - +
chimpanzees + - +
African green 
monkeys
-+ +
rhesus macaques - + +
A3 mice - - -
A3F humans + + - +
A3B humans - - -
A3C humans - + +
A1 rats -
(+) susceptible, (-) not susceptibleRetrovirology 2005, 2:25 http://www.retrovirology.com/content/2/1/25
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Alghough ZAP is extremely efficient againt alphaviruses
and MuLV, it is not clear what role, if any, it plays against
primate retroviruses.
The final level of intracellular immunity deals with viral
assembly and release. Again, HIV-1 encodes another
accessory viral protein u (Vpu), which facilitates the
release of progeny virions from infected cells [108]. Thus,
analogous to the situation with Vif, some cells are "per-
missive" and others are "non-permissive" for viral replica-
tion in the absence of Vpu. Heterokaryons between them
maintain the non-permissive phenotype, which is domi-
nant. Thus, Vpu must counteract some dominant negative
cellular factor, whose identity remains to be determined.
Of interest, recent work suggests that Vpu counteracts the
two-pore K+ (K2P) channel TASK-1, which inhibits the
release of many viruses by an unknown mechanism, pos-
sibly by changing membrane fluidity [109]. Vpu also facil-
itates the release of other retroviruses. By mimicking a
natural component of TASK-1, Vpu is incorporated into
the channel, where it acts as a dominant negative effector.
Vpu also binds β TRCP, an E3 ubiquitin ligase, which
could accelerate the degradation of TASK-1 in the protea-
some [110]. Thus, it is possible that levels and/or poly-
morphisms of TASK-1 are mostly responsible for this
block in the assembly and release of progeny virions.
However, additional experiments are required to make
this connection and/or to reveal additional players in this
last step of the viral replicative cycle in cells.
Intracellular immunity
Several themes emerge from these cell-intrinsic blocks to
retroviral replication. First, the inhibition is broad. Thus,
not only are retroviruses targeted, but other viruses as
well, from HBV and alphaviruses to some mobile genetic
elements, which once were viruses themselves. Second,
multiple steps in the replicative cycles of these viruses are
inhibited, most likely because each mechanism is not
completely effective. This finding might reflect small
differences between extracellular pathogens and normal
cellular homeostatic mechanisms. Alternatively, it might
reflect the vast spectrum of different pathogens, all of
which must be targeted and destroyed. For retroviruses,
the challenge is increased because of their rapid rate of
mutations and their quick adaptation to the host. Third,
these intracellular blocks are more pronounced and effec-
tive in zoonotic infections, where the virus jumps species.
Finally, this inhibition is rapid and targets predominantly
early steps in the replicative cycles of these viruses. Thus,
it tries to prevent the integration of the viral genetic mate-
rial into the host genome. Whether these inhibitors
accomplish this task by targeting viral structures or genetic
material to an endosome, exosome or proteasome, the
end results are the same, i.e. the elimination of the virus.
In this scenario, the outcome depends on the effectiveness
of cellular proteins versus the protective armor of the
virus.
Given these observations, one of the simplest new thera-
peutic interventions could be simply to increase intracel-
lular levels of these antiviral proteins, e.g. TRIM5α ,
APOBEC proteins, ZAP and/or TASK-1. Thus, if we only
understood their normal regulation, it is possible that we
could augment their amounts and activities during active
infections. Of course, as we do not know their other func-
tions in cells, there are also many potential concerns. For
example, would increased levels of APOBEC3G cause
editing of genomic DNA during replication, thus facilitat-
ing oncogenic transformation? Likewise, would increased
amounts of ZAP target critical cellular transcripts for accel-
erated degradation? Alternatively, one could try to block
interactions between Vif and APOBEC proteins and TASK-
1 and Vpu. Possibly, by studying their structures, one
could design inhibitors for their protein-protein interac-
tions. Moreover, all these processes can also be targeted by
gene therapy, by introducing into cells their counterparts
from different species and/or by changing binding sur-
faces of the host proteins so that they no longer interact
with Vif or Vpu, for example. If not practical clinically,
such genetic manipulation would yield important clues as
to which restriction should be targeted by other therapeu-
tic means.
Conclusion
It is remarkable how active are the processes that protect
an organism from internal and external challenges. In
humans, at least three layers of immunity have developed.
Among them, intracellular and innate immune responses
act primarily via pattern recognition, whereas adaptive
immunity is very sequence and peptide-specific. Never-
theless, many pathogens break through and are integrated
into the host genetic material. Thus, some of these defense
mechanism must also survey the movements and effects
of these mobile genetic elements. It appears that a fine
line has been drawn between control and allowing for
some escape as well. As mobile genetic elements contrib-
ute to evolution and fitness of all species, they must be
kept in check, but not eliminated completely and it is pos-
sible that this intricate regulation of hA3G activity in cells
reflects this requirement. On the other hand, there is also
a high price to pay in terms of mistakes, be they develop-
mental defects or cancer. Nevertheless, the study of these
systems that fight extracellular pathogens is likely to
reveal fundamental insights into a plethora of cellular
processes that contribute to human health and disease.
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